Literature DB >> 18781051

Elective cesarean as a risk factor for transfusion after delivery of twins.

Shunji Suzuki1, Yusuke Inde, Miwa Igarashi, Hidehiko Miyake.   

Abstract

We examined deliveries of twins to identify factors most strongly associated with an increased risk of transfusion. We reviewed the obstetric records of 511 twin deliveries at the Japanese Red Cross Katsushika Maternity Hospital from 2003 through 2007. After 18 (3.5%) of these deliveries, transfusions were required. Transfusion was significantly more likely after elective cesarean delivery at a gestational aged of 37 weeks or more (odds ratio, 4.85; 95% confidence interval, 1.87-12.61). Emergency cesarean delivery (at > or =37 weeks' gestation) was not associated with an increased risk of transfusion. The delivery mode of twins should be carefully considered because of the increased risk of transfusion after elective cesarean delivery at a gestational age of 37 weeks or more.

Mesh:

Year:  2008        PMID: 18781051     DOI: 10.1272/jnms.75.247

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  4 in total

Review 1.  Planned caesarean section for women with a twin pregnancy.

Authors:  G Justus Hofmeyr; Jon F Barrett; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2015-12-19

Review 2.  Planned caesarean section for women with a twin pregnancy.

Authors:  G Justus Hofmeyr; Jon F Barrett; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

3.  Outcomes of 'one-day trial of vaginal delivery of twins' at 36-37 weeks' gestation in Japan.

Authors:  Yuria Haruna; Shunji Suzuki
Journal:  Obstet Gynecol Sci       Date:  2019-10-15

4.  In which groups of pregnant women can the caesarean delivery rate likely be reduced safely in the USA? A multicentre cross-sectional study.

Authors:  Jin-Wen Zhang; Ware Branch; Matthew Hoffman; Ank De Jonge; Sheng-Hui Li; James Troendle; Jun Zhang
Journal:  BMJ Open       Date:  2018-08-05       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.